Boston Scientific (NYSE:BSX) said it inked a deal with The Medicines Co. to promote its Promus Premier coronary stent in the U.S.
Promus Premier is the Natick, Mass.-based medtech maker’s next-generation drug-eluting stent, made of a platinum-chromium alloy coated with the anti-restenosis drug everolimus.
Promus Premier won pre-market approval from the FDA in late November and CE Mark approval in the European Union in February.
Parsippany, N.J.-based Medicines Co. will provide promotional support for the Promus beginning next year, according to a press release.
“The Medicines Co.’s established and highly complementary product portfolio in interventional cardiology will enhance the capabilities of our sales force as we introduce the Promus Premier system in the U.S. market. This collaborative agreement brings together 2 of the market leading providers of interventional cardiology and acute care solutions to better support our customers and the patients they serve,” Boston Scientific interventional cardiology global marketing vice president Matt Franklin said in prepared remarks.
BSX shares were up 4.1% to $11.81 apiece as of about 9:45 a.m. today.